6 research outputs found

    From Education to Tumour Characteristics in Colorectal Cancer: An Analysis of the Pathways.

    No full text
    Background: Genetic and environmental factors have been associated with colorectal cancer (CRC) risk. However, their association with prognosis has been less studied. Methods: Path analysis was employed to examine causal pathways from education to environmental (diet, alcohol, smoking, physical activity) and personal factors (screening), and then to obesity and ultimately to tumour characteristics (stage, grade, microsatellite instability (MSI), and site) that are associated with CRC prognosis. Data came from the Ontario Familial Colon Cancer Registry. Pathways were evaluated for effect modification by sex and two indicators of CRC genetic susceptibility (Bethesda criteria and newly identified familial cancer clusters). Results: Four food patterns (healthy foods, high-fat foods, sweet and processed foods, and oriental foods) and four nutrient patterns (total macronutrient, fat vs. carbohydrate, and micronutrients from supplements and from foods) were identified. Education was associated positively with healthy lifestyle factors (e.g. healthy foods factor) and negatively with unhealthy factors (e.g. smoking). As expected, high body mass index (BMI) was associated with lower physical activity and higher fat vs. carbohydrate factor. Unexpectedly, BMI was positively associated with the healthy foods factor among Bethesda positive patients and men. An association between education and BMI was mediated by the healthy foods factor and by physical activity. Important poor prognostic factors, higher grade and stage, were associated with smoking and not being screened. However, unexpected associations included a positive association of physical activity with tumour grade among Bethesda positive patients and a positive association of healthy foods with stage among Bethesda negative patients. Patients with right-sided tumours were more likely to receive micronutrients from supplements, and screening and less likely to smoke, and for men, to have a high BMI, high fat diet and healthy food diet. Conclusion: Some unhealthy lifestyle factors, such as smoking and a high fat food dietary pattern, are associated with adverse CRC tumour characteristics and so may affect the prognosis. Family history may modify some associations though the findings require independent confirmation.Ph

    Cancer in Canada in 2008

    No full text

    Adverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort study

    No full text
    Abstract Background A rise in gastrointestinal (GI) adverse events (AEs) and a decline in bone mineral density (BMD) was observed in patients previously tolerant to brand alendronate shortly after generic versions were introduced in July 2005 to the Canadian market. The objective of our study was to quantify changes in AE rates and BMD scores, as well as associated alendronate discontinuation among patients before and after switch from brand to generic alendronate. Methods A chart review of postmenopausal women 50 years of age and older between 2003 and 2007 was conducted in two specialized tertiary care referral centers. Patients on alendronate both before and after July 2005 were included. The change in the number of AEs, changes in BMD and associated alendronate discontinuation was compared before and after the switch from brand to generic alendronate. Results 301 women with an average age of 67.6 years (standard deviation (SD) = 9.5) had a total of 47 AEs between July 2003 and December 2007 that resulted in discontinuation of the medication. There was a significant increase in the rate of AEs per patient-months-at-risk from 0.0001 before to 0.0044 after October 2005 (p Conclusions Patients who were previously stable on doses of brand alendronate experienced an increase in AEs causing discontinuation after introduction of automatic substitution to generic alendronate. In addition, reductions in BMD were observed in some patients who had stable BMDs before January 2006. Given the substantial increase in AEs, generic alendronate may not be as well tolerated as brand alendronate.</p
    corecore